Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOKYO.L Regulatory News (OKYO)

  • There is currently no data for OKYO

Director's Dealing

11 Feb 2016 07:00

RNS Number : 7144O
West African Minerals Corporation
11 February 2016
 

11 February 2016

For immediate release

West African Minerals Corporation

("WAFM" or the "Company")

Director's dealing

 

The Company announces that it was informed on 10 February 2016 that Plinian Guernsey Limited ("Plinian Guernsey") transferred on 10 February 2016 its entire holding of ordinary shares in the Company to its parent company Plinian Capital Limited ("Plinian Capital"). Brad Mills, a director of the Company, is the controlling shareholder of Plinian Guernsey and also the controlling shareholder of Plinian Capital.

As part of an internal reorganisation, Plinian Guernsey has transferred 32,353,998 ordinary shares of no par value in the Company to Plinian Capital ("WAFM Shares") at their carrying value in Plinian Guernsey's accounts (being US$2,335,605, equivalent to approximately 5 pence per WAFM Share). Following the transfer of the WAFM Shares, Plinian Guernsey has no remaining holding of shares in the Company.

Brad Mills' interest in the share capital of the Company is not affected by the transfer, and remains as follows:

Shareholding

% interest in the issued share capital

Number of Options

Term (from May 2014)

 

Exercise Price (pence)

43,655,233

 

11.45%

4,700,000

10 yrs

10 pence

Number of Warrants

2 years (expiring on 14 February 2016)

 

Exercise Price (pence)

5,071,429

2 yrs

10 pence

 

Note: Brad Mills' interest comprises 1,158,377 Shares that he owns directly; 32,353,998 Shares that are owned by Plinian Capital of which Brad Mills is the controlling shareholder; and a further 10,142,858 Shares that are owned by CE Mining Limited, which is 50 per cent. owned by Plinian Guernsey (CEM) Limited (of which Brad Mills is the controlling shareholder), together with warrants to subscribe for 5,071,429 Shares that are owned by CE Mining Fund II WAFM Limited (a special purpose company established by CE Mining GP II Limited ("Fund GP") in its capacity as general partner of CE Mining Fund II L.P.), which is 100% owned by Fund GP, of which Brad Mills is the indirect controlling shareholder.

 

For further information contact:

West African Minerals Corporation

Brad Mills

 

+44 (0) 20 7730 7486

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish

Michael Cornish

 

+44 (0)20 7628 3396

SP Angel Corporate Finance LLP (Broker)

Ewan Leggat/Katy Birkin

 

+44 (0) 20 3470 0500

ENDS

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGGUAPPUPQGMU
Date   Source Headline
7th Sep 20221:30 pmRNSResult of AGM
30th Aug 20227:00 amRNSQ4 '22 IND planned followed by P2 with AmbioPharm
19th Aug 20227:00 amRNSNotice of AGM
18th Aug 20222:06 pmRNSSecond Price Monitoring Extn
18th Aug 20222:00 pmRNSPrice Monitoring Extension
16th Aug 20227:00 amRNSAnnual Financial Report
9th Jun 20227:08 amRNSDirector/PDMR Shareholding
20th May 20227:00 amRNSDirector/PDMR Shareholding
19th May 20224:01 pmRNSClosing of Offering
18th May 202210:10 amRNSDirector/PDMR Shareholding
17th May 20227:00 amRNSOKYO Announces Pricing of IPO of ADSs in the U.S.
27th Apr 20227:00 amRNSUpcoming Presentations at Ophthalmic Conference
7th Mar 20227:00 amRNSAdditional Listing
23rd Feb 20227:00 amRNSPatent issued: to treat ocular neuropathic pain
21st Feb 20225:00 pmRNSCLN Conversion, exercise of Warrants, equity issue
15th Feb 20227:00 amRNSSuccessful Pre-IND Meeting with the FDA on OK-101
1st Feb 20227:00 amRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSDirector/PDMR Shareholding
26th Jan 20222:05 pmRNSSecond Price Monitoring Extn
26th Jan 20222:00 pmRNSPrice Monitoring Extension
26th Jan 20227:00 amRNSHalf-year Report
14th Dec 20217:00 amRNSU.S. Patent issued for use of OK-101 to treat DED
13th Dec 20217:00 amRNSOK-101:Anti-inflammatory & Pain-Reducing Potential
6th Dec 20217:00 amRNSIND filing Q3 2022 and Phase 2 initiation Q4 2022
1st Dec 20217:00 amRNSDirectorate Change
19th Oct 20214:41 pmRNSSecond Price Monitoring Extn
19th Oct 20214:35 pmRNSPrice Monitoring Extension
19th Oct 20212:05 pmRNSSecond Price Monitoring Extn
19th Oct 20212:00 pmRNSPrice Monitoring Extension
27th Sep 202112:06 pmRNSResult of AGM
9th Sep 20217:00 amRNSNotice of AGM
1st Sep 20217:00 amRNSDirector/PDMR Shareholding
2nd Aug 202111:32 amRNSAnnual Financial Report
29th Jun 20217:00 amRNSResearch Update
17th Jun 20213:58 pmRNSDirectorate Change
12th May 20217:00 amRNSHolding(s) in Company
7th May 202110:07 amRNSAdditional Listing
5th May 202111:53 amRNSPublication of a Prospectus
28th Apr 20217:00 amRNSPositive Data in an Animal Model using OK-201
29th Mar 20217:00 amRNSAppointment of Chief Scientific Officer
3rd Mar 20217:00 amRNSIssue of Equity
1st Mar 20217:00 amRNSIssue of Equity
23rd Feb 20217:00 amRNSPatent for treating Ocular Pain and Inflammation
19th Jan 20217:00 amRNSFiling patent application for the use of Chemerin
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:37 pmRNSPrice Monitoring Extension
14th Jan 20212:05 pmRNSSecond Price Monitoring Extn
14th Jan 20212:00 pmRNSPrice Monitoring Extension
7th Jan 20217:00 amRNSDirectorate Change
30th Nov 20207:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.